Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | IMVT |
---|---|---|
09:32 ET | 3036 | 26.095 |
09:36 ET | 500 | 26.085 |
09:38 ET | 600 | 26.085 |
09:39 ET | 1200 | 26.085 |
09:41 ET | 100 | 26.22 |
09:43 ET | 400 | 26.22 |
09:45 ET | 500 | 26.33 |
09:48 ET | 7418 | 26.27 |
09:50 ET | 6052 | 26.34 |
09:52 ET | 463 | 26.335 |
09:54 ET | 950 | 26.235 |
10:01 ET | 906 | 26.1 |
10:03 ET | 400 | 26.055 |
10:08 ET | 400 | 26.01 |
10:10 ET | 100 | 26.045 |
10:12 ET | 1226 | 26.04 |
10:14 ET | 882 | 25.985 |
10:15 ET | 1560 | 26.015 |
10:17 ET | 200 | 26.01 |
10:19 ET | 425 | 26 |
10:21 ET | 100 | 26 |
10:24 ET | 623 | 25.97 |
10:26 ET | 200 | 26.02 |
10:28 ET | 400 | 26.04 |
10:30 ET | 393 | 26.05 |
10:32 ET | 1751 | 26.11 |
10:33 ET | 800 | 26.12 |
10:35 ET | 800 | 26.095 |
10:37 ET | 100 | 26.02 |
10:39 ET | 413 | 26.09 |
10:46 ET | 1336 | 26.22 |
10:48 ET | 5837 | 26.2 |
10:50 ET | 500 | 26.15 |
10:51 ET | 700 | 26.135 |
10:53 ET | 521 | 26.14 |
10:55 ET | 1750 | 26.125 |
10:57 ET | 200 | 26.115 |
11:00 ET | 1499 | 26.055 |
11:02 ET | 1493 | 26.025 |
11:04 ET | 250 | 26.05 |
11:06 ET | 1093 | 26.12 |
11:08 ET | 1959 | 26.26 |
11:09 ET | 644 | 26.25 |
11:13 ET | 1005 | 26.25 |
11:15 ET | 610 | 26.195 |
11:20 ET | 100 | 26.23 |
11:22 ET | 1558 | 26.21 |
11:24 ET | 200 | 26.18 |
11:26 ET | 3828 | 26.14 |
11:27 ET | 500 | 26.14 |
11:29 ET | 502 | 26.15 |
11:31 ET | 1005 | 26.12 |
11:33 ET | 300 | 26.0981 |
11:36 ET | 100 | 26.1 |
11:38 ET | 700 | 26.125 |
11:40 ET | 1346 | 26.14 |
11:42 ET | 2002 | 26.12 |
11:44 ET | 300 | 26.13 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Immunovant Inc | 3.8B | -13.8x | --- |
Avidity Biosciences Inc | 3.9B | -12.8x | --- |
Crinetics Pharmaceuticals Inc | 3.5B | -11.7x | --- |
Dyne Therapeutics Inc | 3.4B | -8.6x | --- |
Immunitybio Inc | 4.3B | -6.0x | --- |
Merus NV | 3.6B | -19.5x | --- |
Immunovant, Inc. is a clinical-stage immunology company. The Company is focused on developing treatments for patients with autoimmune diseases. Its product pipeline includes batoclimab and IMVT-1402, both of which are novel, fully human monoclonal antibodies that target the neonatal fragment crystallizable receptor (FcRn). Batoclimab is a subcutaneous injection with dosing. Batoclimab is observed to reduce immunoglobulin G (IgG) antibodies that cause inflammation and disease. Its product candidate, batoclimab, is dosed in small volumes and with a 27-gauge needle. It is developing batoclimab for myasthenia gravis (MG), thyroid eye disease (TED), chronic inflammatory demyelinating polyneuropathy (CIDP) and Graves’ disease (GD). Its lead product candidate IMVT-1402 has also been observed to reduce IgG antibody levels in a Phase I clinical trial conducted in healthy adults. IMVT-1402 is a fully human monoclonal antibody that inhibits FcRn.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.8B |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 146.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.71 |
EPS | $-1.89 |
Book Value | $4.24 |
P/E Ratio | -13.8x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.